Euro-Med Laboratories Phils Inc
Euro-Med Laboratories Phils Inc operates in Pharmaceuticals.
Euro-Med Laboratories Phils Inc (EURO) - Net Assets
Latest net assets as of December 2022: ₱5.71 Billion PHP
Based on the latest financial reports, Euro-Med Laboratories Phils Inc (EURO) has net assets worth ₱5.71 Billion PHP as of December 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₱10.06 Billion) and total liabilities (₱4.35 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₱5.71 Billion |
| % of Total Assets | 56.76% |
| Annual Growth Rate | 1.81% |
| 5-Year Change | 6.76% |
| 10-Year Change | N/A |
| Growth Volatility | 1.24 |
Euro-Med Laboratories Phils Inc - Net Assets Trend (2014–2022)
This chart illustrates how Euro-Med Laboratories Phils Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Euro-Med Laboratories Phils Inc (2014–2022)
The table below shows the annual net assets of Euro-Med Laboratories Phils Inc from 2014 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | ₱5.71 Billion | +1.21% |
| 2021-12-31 | ₱5.64 Billion | +3.54% |
| 2020-12-31 | ₱5.45 Billion | -0.15% |
| 2019-12-31 | ₱5.46 Billion | +2.03% |
| 2018-12-31 | ₱5.35 Billion | +3.25% |
| 2017-12-31 | ₱5.18 Billion | +2.45% |
| 2016-12-31 | ₱5.06 Billion | +2.02% |
| 2015-12-31 | ₱4.96 Billion | +0.22% |
| 2014-12-31 | ₱4.94 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Euro-Med Laboratories Phils Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 96.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₱1.55 Billion | 27.09% |
| Common Stock | ₱4.11 Billion | 72.03% |
| Other Components | ₱50.09 Million | 0.88% |
| Total Equity | ₱5.71 Billion | 100.00% |
Euro-Med Laboratories Phils Inc Competitors by Market Cap
The table below lists competitors of Euro-Med Laboratories Phils Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Big Gold Inc.
F:H7L
|
$155.20 |
|
Beco Steel Ltd
KAR:BECO
|
$155.27 |
|
CORAZON GOLD
BE:2CG
|
$155.29 |
|
BRI AGRO
BE:0R8
|
$155.44 |
|
Oncimmune Holdings plc
LSE:ONC
|
$155.03 |
|
First Al-Noor Modaraba
KAR:FANM
|
$154.99 |
|
RISANAMENTO
MU:RN5
|
$154.79 |
|
Alsons Consolidated Resources Inc
PSE:ACR
|
$154.51 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Euro-Med Laboratories Phils Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 5,640,677,500 to 5,708,922,250, a change of 68,244,750 (1.2%).
- Net income of 199,887,400 contributed positively to equity growth.
- Dividend payments of 143,924,920 reduced retained earnings.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₱199.89 Million | +3.5% |
| Dividends Paid | ₱143.92 Million | -2.52% |
| Other Changes | ₱12.28 Million | +0.22% |
| Total Change | ₱- | 1.21% |
Book Value vs Market Value Analysis
This analysis compares Euro-Med Laboratories Phils Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.73x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₱1.23 | ₱1.01 | x |
| 2017-12-31 | ₱1.26 | ₱1.01 | x |
| 2018-12-31 | ₱1.30 | ₱1.01 | x |
| 2019-12-31 | ₱1.33 | ₱1.01 | x |
| 2020-12-31 | ₱1.32 | ₱1.01 | x |
| 2021-12-31 | ₱1.37 | ₱1.01 | x |
| 2022-12-31 | ₱1.39 | ₱1.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Euro-Med Laboratories Phils Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.73%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 1.76x
- Recent ROE (3.50%) is below the historical average (5.11%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 4.19% | 4.40% | 0.49x | 1.94x | ₱-287.26 Million |
| 2015 | 4.68% | 5.20% | 0.49x | 1.84x | ₱-263.72 Million |
| 2016 | 6.03% | 6.31% | 0.52x | 1.84x | ₱-200.83 Million |
| 2017 | 6.67% | 6.71% | 0.57x | 1.74x | ₱-172.71 Million |
| 2018 | 6.99% | 7.18% | 0.54x | 1.81x | ₱-160.84 Million |
| 2019 | 7.13% | 6.84% | 0.55x | 1.89x | ₱-156.75 Million |
| 2020 | 3.86% | 5.49% | 0.38x | 1.85x | ₱-334.73 Million |
| 2021 | 3.00% | 4.71% | 0.37x | 1.72x | ₱-395.02 Million |
| 2022 | 3.50% | 4.73% | 0.42x | 1.76x | ₱-371.00 Million |
Industry Comparison
This section compares Euro-Med Laboratories Phils Inc's net assets metrics with peer companies in the Pharmaceuticals industry.
No peer company data available for comparison.